Zydus Lifesciences Reports Positive Phase II(b) Trial Results for MASH Treatment

189 subjects enrolled across USA, Turkey, and Argentina; 26.5% treatment difference achieved against placebo.

Reader Takeaway: Positive global trial data validates Saroglitazar efficacy, but significant regulatory hurdles remain for US and EU entry.

What just happened

Zydus Lifesciences has successfully concluded the EVIDENCES-X Phase II(b) clinical trial for its investigational drug, Saroglitazar Magnesium. The study, conducted over 52 weeks, focused on patients suffering from Metabolic dysfunction Associated Steatohepatitis (MASH) and fibrosis. The trial achieved its primary endpoint of resolving steatohepatitis without worsening fibrosis, outperforming the placebo group by 26.5%.

Why this matters

MASH is a chronic liver disease with a high global unmet medical need and very few approved treatment options. By demonstrating efficacy in a global, multicentre setting, Zydus has cleared a major hurdle in proving the drug’s potential for international markets. This data will serve as a foundational element for future discussions with global health regulators.

Regulatory Status

Saroglitazar Magnesium is currently approved in India for MASH and MASLD (Metabolic dysfunction Associated Steatotic Liver Disease) since 2020. However, the drug is still considered an investigational compound in the US and the European Union. It has not yet received approval from the FDA or the EMA, meaning the company must still navigate complex clinical and regulatory pathways before commercialization in these regions.

What changes now

The company plans to present these findings at upcoming scientific conferences and submit the data for peer-reviewed publication. This will increase the visibility of their R&D efforts among the global medical community. Investors should keep a close watch on future announcements regarding formal meetings with the US FDA or European counterparts regarding Phase III plans.

Risks to watch

Clinical success in a Phase II(b) trial does not guarantee approval in the US or EU. Future Phase III trials will be larger, costlier, and subject to stricter regulatory scrutiny. Any delay in the regulatory process or failure to replicate these results in larger cohorts could impact future growth prospects.